Pliva Generics Company Intelligence Report

Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.

• Executive Summary
• Introduction
  • Pliva delists from London Stock Exchange
  • Products
  • Biosimilars
  • Pliva, Pliva Hrvatska and Pliva Lachema ANDA Approvals, 2002-09
  • Sidmak Laboratories ANDA Approvals, 2002-05
  • Recent product approvals
  • Topiramate
  • Irinotecan hydrochloride
  • PLIVA-Lachema's generic Aredia approved for US market
  • Venlafaxine
  • Paclitaxel injection
  • Financial results
  • Latest results nine months 2008
  • Pliva: Nine Month Results, in HRK000s
  • Pliva: Nine Month Results, in US$000s
  • Latest fiscal year results, FY2007
  • Latest Full Year Results, Fiscal Year to 31 December 2006 2007 in HRK000s
  • Latest Full Year Results, Fiscal Year to 31 December 2006 - 2007 in US$000s
  • Geographical Data
  • Latest Full Year Results by Region, Fiscal Year to 31 December 2006 2007 in HRK000s
  • Latest Full Year Results by Region, Fiscal Year to 31 December 2006 - 2007 in US$000s
• Major developments
  • Mergers, acquisitions and agreements
  • Pliva divests Spanish operations
  • Pliva divests Italian operations to Biomedica
  • Pliva to acquire ORCApharm
  • Barr successfully acquires Pliva
  • Litigation
  • California court rules branded firms can be liable for generics
  • Barr confirms patent challenge regarding UCB's Xyzal
  • Contact Details